ASX:KZAKazia Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kazia Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.40 +0.01 (+2.56 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.38Now: A$0.40▼A$0.4050-Day RangeA$0.39MA: A$0.41▼A$0.4552-Week RangeA$0.32Now: A$0.40▼A$0.80Volume47,736 shsAverage VolumeN/AMarket Capitalization$28.87 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Kazia Therapeutics. Previous Next 2.4 Community Rank Outperform VotesKazia Therapeutics has received 14 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKazia Therapeutics has received 15 “underperform” votes. (Add your “underperform” vote.)Community SentimentKazia Therapeutics has received 51.72% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kazia Therapeutics and other stocks. Vote “Outperform” if you believe KZA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KZA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKazia Therapeutics does not currently pay a dividend.Dividend GrowthKazia Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kazia Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$51,375.00 in company stock and sold A$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Kazia Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kazia Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKazia Therapeutics has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.08 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:KZA Previous Symbol CUSIPN/A CIKN/A Webwww.kaziatherapeutics.com Phone61 2 9472 4101Debt Debt-to-Equity RatioN/A Current Ratio2.44 Quick Ratio2.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.40 million Price / Sales20.66 Cash FlowA$0.09 per share Price / Cash Flow4.49 Book ValueA$0.17 per share Price / Book2.35Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares72,166,704Market Cap$28.87 million Next Earnings DateN/A OptionableNot Optionable Receive KZA News and Ratings via Email Sign-up to receive the latest news and ratings for KZA and its competitors with MarketBeat's FREE daily newsletter. Kazia Therapeutics (ASX:KZA) Frequently Asked Questions How has Kazia Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Kazia Therapeutics' stock was trading at A$0.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KZA shares have decreased by 32.2% and is now trading at A$0.40. View which stocks have been most impacted by Coronavirus. Has Kazia Therapeutics been receiving favorable news coverage? Headlines about KZA stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kazia Therapeutics earned a coverage optimism score of -2.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutKazia Therapeutics. Who are some of Kazia Therapeutics' key competitors? Some companies that are related to Kazia Therapeutics include CorMedix (CRMD), Predictive Technology Group (PRED), Cohbar (CWBR), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), Ibio (IBIO), Circassia Pharmaceuticals (CIR), Orgenesis (ORGS), Ampio Pharmaceuticals (AMPE), AquaBounty Technologies (AQB), Novoheart (NVH), Immunoprecise Antibodies (IPA) and Omega Diagnostics Group (ORPH). View all competitors. Who are Kazia Therapeutics' key executives? Kazia Therapeutics' management team includes the following people: Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)Ms. Gabrielle Heaton, Director of Fin. & Admin.Ms. Catherine Jane Hill, Company Sec. (Age 60)Kym Robins, Director of Marketing & CommunicationsDr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program What is Kazia Therapeutics' stock symbol? Kazia Therapeutics trades on the ASX under the ticker symbol "KZA." What is Kazia Therapeutics' stock price today? One share of KZA stock can currently be purchased for approximately A$0.40. How big of a company is Kazia Therapeutics? Kazia Therapeutics has a market capitalization of $28.87 million and generates $1.40 million in revenue each year. What is Kazia Therapeutics' official website? The official website for Kazia Therapeutics is www.kaziatherapeutics.com. How can I contact Kazia Therapeutics? The company can be reached via phone at 61 2 9472 4101. This page was last updated on 6/1/2020 by MarketBeat.com Staff
